January 2015, Volume 1, Issue 1

January 2015

Volume 1, Issue 1

This issue features breakthrough research from the 2014 ASH Annual Meeting, a look at changing definitions of value, a debate over transplant in AML patients, and more.

Table of Contents

January 2015

What Can We Do? The Scope of APP Practice Patterns

Thursday, January 1st, 2015
As I opened the door to the exam room one sunny morning in Cleveland, Ohio, a patient stood to greet me. “Congratulations, you’re finally a...

A New Year, A New Set of Resolutions

Thursday, January 1st, 2015
It's the dawn of a new year, and I’m sure this is one of many columns in many different publications you will read in...

January 2015

Fred Hutch Names New President and Director, and more

Thursday, January 1st, 2015
Gary Gilliland Named as Fred Hutch’s New President and Director On January 2, Gary Gilliland, MD, PhD, began his term as the new president and...

Fighting Back Against Cutbacks and Highlights from the ASH Practice Partnership Lunch

Thursday, January 1st, 2015
Fighting Back Against Cutbacks: ASH Announces Fourth-Round of Bridge Grant Recipients Biomedical researchers are operating in a tepid – lukewarm, at best – funding environment....

January 2015

Behind the Music: Armand Keating, MD

Thursday, January 1st, 2015
If you’ve attended the the general session room at the ASH annual meeting in the past eight years or so, you’ve likely heard the musical interludes...

To Transplant or Not To Transplant in First Remission?

Thursday, January 1st, 2015
Most patients with newly diagnosed acute myeloid leukemia (AML) will achieve a first complete remission with standard induction chemotherapy. Durable remission or cure can only be attained, though, with further treatment...

Defining “Value” in Value-Based Medicine: A Work in Progress

Thursday, January 1st, 2015
Achieving optimal patient outcomes is still one of the most important aspects of health care. In recent years, a new goal – and one...

Pulling Back the Curtain: Stephanie Lee, MD, MPH

Thursday, January 1st, 2015
What was your first job? I was a babysitter when I was younger, like everybody probably was. In elementary school, though, I picked blueberries for...

January 2015

Instruction Without Lecture: Losing the Crutch

Thursday, January 1st, 2015
Despite being an inefficient way to educate people, the lecture has remained the most commonly employed method for delivering course material in medical schools....

Understanding Non-Hodgkin Lymphoma

Thursday, January 1st, 2015
There are two major types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). NHL is the sixth most common cancer in men and the...

Is it reasonable to use rivaroxaban as an antithrombotic drug in obese patients?

Thursday, January 1st, 2015
This month, Kenneth A. Bauer, MD, advises on the use of target-specific oral anticoagulants in obese patients.Is it reasonable to use rivaroxaban as an antithrombotic...

January 2015

Clone Wars: Catching Cancer Before it Starts?

Thursday, January 1st, 2015
A pair of studies recently published in The New England Journal of Medicine have uncovered an easily detectable “premalignant” state in the blood critical to the development of blood cancer....
WIB_icon

TIDEL-II: Individualized Approach to Imatinib Yields Promising Results

Thursday, January 1st, 2015
For patients with chronic-phase chronic myeloid leukemia (CPCML), a strategy of intensifying treatment with imatinib or selective switching to nilotinib based on molecular treatment targets leads to improved overall survival,...

New Agent PER977 Shows Promise in Reversing Anticoagulation

Thursday, January 1st, 2015
Although newer target-specific oral anticoagulants represent great advances in the prevention and treatment of blood clots, their use is limited by a lack of effective reversal agents. Severe...

Many Younger Patients Receive Inappropriate First-Line Care

Thursday, January 1st, 2015
Nearly one-third of adolescent and young adult patients diagnosed with cancer do not receive appropriate therapy, according to recent research published in the Journal of the National Cancer Institute. The...

Making Blood Transfusions Safer, New Indication for Ruxolitinib, and more

Thursday, January 1st, 2015
FDA Approves System to Make Blood Transfusions Safer The U.S. Food and Drug Administration (FDA) approved the Intercept Blood System, a new system designed to...

ATTRACT, PD-1 Blockade, and more

Thursday, January 1st, 2015
LEUKEMIA Selected by David Steensma, MD Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (NCT02055781) Study Design: Randomized, open-label, parallel assignment safety/efficacy study Study...
WIB_icon

Brentuximab Vedotin: Changing the Landscape for Relapsed/Refractory Hodgkin Lymphoma Patients?

Thursday, January 1st, 2015
For the approximately 50 percent of patients with relapsed/refractory Hodgkin lymphoma who do not respond to autologous stem cell  transplantation (auto-SCT), the antibody-drug conjugate brentuximab vedotin produced durable response and survival, according to...
WIB_icon

Phase 2 Results of the Carfilzomib, Thalidomide, and Dexamethasone (KTd) Regimen in Multiple Myeloma...

Thursday, January 1st, 2015
Appropriate selection of induction and consolidation chemotherapy regimens is essential to achieving the maximum response and improving outcomes for patients with multiple myeloma (MM) planning to undergo...

January 2015

Rising Cost of Cancer Drugs: Is There an End in Sight?

Thursday, January 1st, 2015
In 2013, U.S. health-care spending continued its relentless climb, reaching $2.9 trillion, far outspending any other developed nation.¹ About $271.1 billion of that – or almost one...

New Compound Boosts Healthy Red Blood Cell Production, Lowers Anemia Burden in β-Thalassemia

Thursday, January 1st, 2015
ACE-536, a recombinant fusion protein containing modified activin receptor type IIB and IgG Fc, has shown promising results in the treatment of β-thalassemia, reducing the need for...

HSCT Could Become Standard of Care for HIV-Positive Patients with Lymphoma

Thursday, January 1st, 2015
Results from a multi-institutional trial presented at ASH 2014 debunk the common myth that HIV-positive patients with lymphoma might not be suitable for autologous hematopoietic stem cell...

CAR T Therapies: Engineering a Breakthrough in Lymphoma and Leukemia Treatment

Thursday, January 1st, 2015
Novel therapies that harness the body’s own immune cells to attack cancer cells took center stage at this year’s annual meeting. Across a variety of...

2014 ASH Annual Meeting: Late But Certainly Not Least…

Thursday, January 1st, 2015
This year’s six late-breaking abstracts feature innovative research in preventing bleeding risk, better prediction tools in Hodgkin lymphoma, and new approaches for high-risk, difficult-to-treat...

SHARE